Raymond James analyst maintained a Buy rating on Sionna Therapeutics, Inc. today and set a price target of $45.00. The company’s shares closed yesterday at $30.91.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sionna Therapeutics, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $39.50.
Based on Sionna Therapeutics, Inc.’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $18.07 million. In comparison, last year the company had a GAAP net loss of $11.88 million
Read More on SION:
Disclaimer & DisclosureReport an Issue
- Sionna Therapeutics appoints Caroline Stark Beer as CBO
- Sionna Therapeutics initiated with a Buy at JonesResearch
- Buy Rating for Sionna Therapeutics: Innovative Cystic Fibrosis Treatments with Promising Clinical Trials
- Short Report: Frontier Group short positioning continues gaining altitude
- Sionna Therapeutics initiated with a Sector Perform at RBC Capital
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/A%20Palantir%20sign%20displayed%20on%20an%20office%20building%20by%20Poetra_RH%20via%20Shutterstock.jpg)
